Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07783594
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Epcoritamab — DRUG
    Given by Injection
  • Observation — OTHER
    Participant will be closely monitored until the disease gets worse and requires treatment, as determined by your treating doctor or at your request.

Study Details

To compare the time to next treatment between patients with previously untreated, low tumor burden FL who receive the study drug epcoritamab versus those who do not receive epcoritamab and are monitored only.

Key Dates

First listed
Aug 25, 2026
Start date
Feb 12, 2027
Status verified
Aug 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2030

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: EPCORI Arm
  • Experimental: OBS Arm

Primary Outcome Measure

Safety and adverse events (AEs). [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UT MD Anderson Cancer CenterHoustonTexas77030
Dai Chihara, MD
[email protected]
713-563-5426
Dai Chihara, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
UT MD Anderson Cancer Center· Houston, TX

Related Studies